Pulse Biosciences, Inc. Files 8-K with SEC Detailing Company Information and Nasdaq Listing
Pulse Biosciences, Inc. announced the enrollment of the first patients in its pivotal NANOPULSE-AF IDE clinical study for its nPulse™ Cardiac Catheter System, which uses non-thermal irreversible electroporation (nsPFA) to treat atrial fibrillation. This milestone is crucial for potential FDA approval and market entry, representing a significant step for the company’s proprietary Nano-Pulse Stimulation™ technology platform. The company's stock, trading on Nasdaq under PLSE, is highly sensitive to the study's outcomes.
First patients treated in Pulse Biosciences (NASDAQ: PLSE) NANOPULSE-AF AFib trial
Pulse Biosciences has announced the enrollment and treatment of the first seven patients in its NANOPULSE-AF IDE pivotal clinical study for recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The study aims to enroll approximately 215 participants across the U.S. and Europe, evaluating procedural success and safety at 6 and 12 months post-ablation. This follows a successful feasibility trial that demonstrated high procedural success rates using the nPulse™ Cardiac Catheter System, which utilizes nanosecond pulsed field ablation energy.
Pulse Biosciences (NASDAQ: PLSE) recently announced that its pivotal clinical study of the Npulse™ Cardiac Catheter System for atrial fibrillation treatment (Nanopulse-Af Ide) has completed enrollment of the first group of patients.
Pulse Biosciences (NASDAQ: PLSE) announced the completion of enrollment for the first group of patients in its pivotal clinical study of the Npulse™ Cardiac Catheter System. This study, known as Nanopulse-AF IDE, is designed to assess the safety and efficacy of the system for treating atrial fibrillation. This milestone signifies a critical advancement in the company's research and development efforts in this medical field.
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
Pulse Biosciences has enrolled the first patients in its NANOPULSE-AF IDE Pivotal Clinical Study. This study is designed to evaluate the nPulse™ Cardiac Catheter System for the treatment of Atrial Fibrillation. The news was reported by Refinitiv.
Is It Too Late To Consider Pulse Biosciences (PLSE) After Recent Share Price Surge?
Pulse Biosciences (PLSE) has seen significant share price appreciation, raising questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is overvalued at $23 per share, with an intrinsic value around $2.61. The company's Price-to-Book (P/B) ratio of 19.39x also significantly exceeds the industry average, indicating potential overvaluation.
How Pulse Biosciences Inc (PLSE) Affects Rotational Strategy Timing
This article analyzes Pulse Biosciences Inc (PLSE) through a rotational strategy timing lens, highlighting strong near-term sentiment but a neutral mid and long-term outlook. It presents AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes elevated downside risk due to a lack of additional long-term support signals.
Pulse Biosciences (PLSE) awards CTO 100,000 Restricted Stock Units
Pulse Biosciences (PLSE) has granted its Chief Technology Officer, Darrin Uecker, 100,000 Restricted Stock Units (RSUs) as a compensation award. These RSUs represent a contingent right to receive one share of common stock for each unit, with full vesting scheduled for March 23, 2029, dependent on Uecker's continued service to the company. This transaction is classified as stock-based compensation rather than an open-market purchase or sale.
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Pulse Biosciences, Inc. announced its plan to present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 9:30 am ET. The company, known for its nPulse™ platform using Nanosecond Pulsed Field Ablation (nsPFA™), aims to improve patients' quality of life through novel bioelectric medicine. A webcast of the presentation will be available on the company's investor website.
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Pulse Biosciences announced its plan to present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, at 10:30 AM ET. The company will provide a live and recorded webcast of the presentation on its investor website. Pulse Biosciences is focused on developing its nPulse™ technology for non-thermal cell clearance, particularly for atrial fibrillation treatment and surgical soft tissue ablation.
PLSE SEC Filings - Pulse Biosciences Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Pulse Biosciences (PLSE) SEC filings, including annual, quarterly, and material event reports, alongside insider trading forms. It features AI-powered summaries to help interpret complex documents and track key milestones, financial performance, and governance matters for the medical device developer. The platform allows investors, analysts, and clinicians to quickly understand the implications of these filings and monitor insider transactions.
PLSE SEC Filings - Pulse Biosciences Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Pulse Biosciences (PLSE) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms, with AI-powered summaries. Recent filings highlight an updated investor presentation, the appointment of Maria Sainz to the board, FDA approval for a clinical study on atrial fibrillation, and Q3 2025 financial results. The platform aims to help investors quickly understand the implications of these regulatory documents.
Pulse Biosciences Shifts Focus to Catheter Electrophysiology Tech
Pulse Biosciences Inc. is strategically re-aligning its focus and capital allocation to prioritize the development and commercialization of its nPulse Cardiac Catheter Ablation System. This decision is driven by compelling European feasibility study data from over 150 patients, which demonstrated unprecedented clinical outcomes in treating atrial fibrillation with superior speed, safety, and long-term efficacy. The company plans to dedicate the majority of its R&D and clinical investment to this program, including an upcoming pivotal IDE study in the United States and Europe.
How Pulse Biosciences’ nPulse AFib Refocus Will Impact Pulse Biosciences (PLSE) Investors
Pulse Biosciences (PLSE) is shifting its focus to accelerate the development and commercialization of its nPulse Cardiac Catheter Ablation System for Atrial Fibrillation, driven by positive European feasibility data. This strategic refocus, moving capital towards electrophysiology and streamlining other areas, is expected to reshape the company's investment narrative. Investors should consider how this concentration of resources on the promising AFib data could impact future clinical trials, regulatory approvals, and competitive landscape within the electrophysiology market.
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7% - What's Next?
Pulse Biosciences (NASDAQ:PLSE) experienced a 7% stock decline during mid-day trading on Monday, with shares trading as low as $20.06 on significantly reduced volume. Analysts are currently mixed, with a consensus "Hold" rating and an average price target of $30. Recent insider selling has been observed, however, institutional investors have increased their holdings in the company.
How Pulse Biosciences’ nPulse AFib Refocus Will Impact Pulse Biosciences (PLSE) Investors
Pulse Biosciences recently announced a shift in focus towards its nPulse Cardiac Catheter Ablation System, accelerating its development and commercialization efforts after positive European feasibility data for Atrial Fibrillation. This strategic refocus, moving capital to the electrophysiology program and streamlining other areas, will likely reshape the company's investment narrative. Investors should note that while the nPulse data is promising, the company still faces significant growth targets and clinical, regulatory, and competitive risks.
PLSE Stock News Today | Earnings, Events & Price Alerts
Pulse Biosciences (PLSE) is accelerating the development and commercialization of its nPulse Cardiac Catheter Ablation System, evidenced by promising European feasibility data showing high procedural success and durable efficacy in treating Atrial Fibrillation. The company is reallocating capital to prioritize this program, while also reporting positive long-term clinical data for its Vybrance Percutaneous Electrode System in treating benign thyroid nodules. These developments highlight Pulse Biosciences' focus on innovative medical device solutions.
Pulse Biosciences Grants RSUs to Chief Technology Officer
Pulse Biosciences recently granted its Chief Technology Officer, Darrin R. Uecker, 100,000 restricted stock units (RSUs) that will vest in full on the third anniversary of the grant date. This action aligns Uecker's incentives with advancing the company's atrial fibrillation product development and fostering long-term shareholder value. While the company faces weak financial performance, it shows strong technical momentum and encouraging clinical progress, with the latest analyst rating on PLSE stock being a Hold with a $22.50 price target.
Pulse Biosciences (NASDAQ: PLSE) awards CTO 100,000-share RSU grant
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced that its Compensation Committee granted Chief Technology Officer Darrin R. Uecker a restricted stock unit (RSU) award covering 100,000 shares of common stock. This grant recognizes his contributions to the company's product development, particularly for atrial fibrillation treatments. The RSUs are set to vest in full on the third anniversary of the grant date, aligning the CTO's incentives with the company's long-term performance.
PLSE Speeds Up Cardiac Catheter Initiative Following Landmark AFib Findings
Pulse Biosciences (PLSE) is re-prioritizing its resources to fast-track its nPulse Cardiac Catheter Ablation System following promising results from a European feasibility study for atrial fibrillation (AFib). The system demonstrated a 100% procedural success rate at six months and a strong safety profile, leading the company to channel most of its R&D investment into this program with a pivotal IDE study planned for the U.S. and Europe. This strategic shift aims to capitalize on the expanding electrophysiology ablation market, projected to reach $8.01 billion by 2026.
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Pulse Biosciences (PLSE) is accelerating its nPulse Cardiac Catheter Ablation System program after reporting breakthrough clinical results from its European feasibility study for Atrial Fibrillation (AFib) treatment. The system showed 100% procedural success at six months and a 96% sustained success rate at 12 months, leading the company to reallocate resources to this high-priority initiative. This strategic shift aims to capitalize on a rapidly growing electrophysiology market, positioning PLSE for significant long-term growth.
(PLSE) and the Role of Price-Sensitive Allocations
This article from Stock Traders Daily analyzes Pulse Biosciences Inc (PLSE) using AI models, highlighting conflicting sentiment across different time horizons and suggesting choppy conditions. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for various risk profiles, along with specific entry, target, and stop-loss levels. The analysis emphasizes an exceptional short setup with a favorable risk-reward ratio, indicating potential downside.
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot
Pulse Biosciences (PLSE) has put its nPulse Cardiac Catheter Ablation System at the forefront of its strategy, buoyed by European feasibility data in Atrial Fibrillation and upcoming pivotal studies. Despite a significant share price increase over the past year, with a 90-day return of 45.39%, analysts suggest the stock is fairly valued around $22, implying that future growth expectations are already priced in. The company's advancement in clinical programs for nPulse, aiming for a high-value EP and cardiac surgery market, is a key driver for its valuation, but its success relies on clear outperformance of existing treatments and managing expenses.
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter Platform - Has The Bull Case Changed?
Pulse Biosciences has recently shifted its focus and capital allocation to accelerate the development of its nPulse Cardiac Catheter Ablation System, following strong European feasibility data for atrial fibrillation patients. This strategic move concentrates resources on a single electrophysiology platform, with early data suggesting potential for speed, safety, and durable pulmonary vein isolation. The company projects significant revenue growth by 2028, with current forecasts aligning with its fair value.
Pulse Biosciences targets CE mark submission in 2026 as nPulse platform advances clinical milestones
Pulse Biosciences is aiming for CE mark submission in 2026 for its nPulse platform, which is designed for dermatology and aesthetics. The company's recent Q4 2023 earnings call highlighted advancements in clinical trials using the nPulse device, showing promising results for benign skin lesions and underscoring its potential market impact.
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter Platform - Has The Bull Case Changed?
Pulse Biosciences (PLSE) has seen a 14.8% increase after shifting its capital to accelerate the development of its nPulse Cardiac Catheter Ablation System, based on strong European feasibility data for atrial fibrillation. This strategic refocus concentrates resources on a single electrophysiology platform, which early data indicates offers a promising mix of speed, safety, and durable pulmonary vein isolation. The company projects significant revenue and earnings growth by 2028, supported by optimistic analyst forecasts, though risks like slow adoption and reimbursement uncertainty remain.
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
Pulse Biosciences has announced a strategic realignment to prioritize and accelerate the development and commercialization of its nPulse™ Cardiac Catheter Ablation System, following exceptional long-term clinical data from a European feasibility study. The data, presented at the 31st Annual AF Symposium, showed 100% procedural success at 6 months and 96% sustained success at 12 months in treating Atrial Fibrillation (AFib). The company is now dedicating the majority of its R&D and clinical investment to this program, adjusting focus from other areas like surgical and percutaneous soft-tissue ablation.
Pulse Biosciences Announces Organizational Realignment to Accelerate Cardiac Catheter Program After Exceptional AFib Clinical Results
Pulse Biosciences (Nasdaq: PLSE) announced an organizational realignment to prioritize its nPulse Cardiac Catheter System for atrial fibrillation (AFib) treatment, following "unprecedented" clinical data. The company will reallocate resources from cardiac surgery programs to focus on the high-growth electrophysiology (EP) market, including reducing sales and marketing headcount while increasing product development recruitment. This strategic shift aims to accelerate market penetration and leverage its strong clinical results, which include a low 1.3% rate of Serious Adverse Events.
Pulse Biosciences (PLSE) realigns strategy around nPulse AFib catheter program
Pulse Biosciences has announced a strategic and organizational realignment, shifting its focus and resources towards the development and commercialization of its nPulse Cardiac Catheter Ablation System for treating atrial fibrillation. This decision follows strong feasibility data from a European study, demonstrating significant efficacy and safety. The company will reduce headcount in sales and marketing while increasing hiring for product development roles to accelerate its electrophysiology program.
AFib catheter posts 96% 12-month success; Pulse Biosciences shifts focus
Pulse Biosciences (Nasdaq: PLSE) is strategically realigning its focus and capital allocation to accelerate the development and commercialization of its nPulse™ Cardiac Catheter Ablation System, following exceptional long-term clinical data. The European feasibility study showed 96% sustained success at 12 months for treating Atrial Fibrillation (AFib) with high procedural efficiency and a low rate of serious adverse events. The company will now prioritize its EP market development program, including an upcoming pivotal IDE study in the U.S. and Europe, while calibrating its surgical and soft-tissue ablation programs.
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter Platform - Has The Bull Case Changed?
Pulse Biosciences (PLSE) has shifted its focus to accelerate the development of its nPulse Cardiac Catheter Ablation System, following promising European feasibility data for atrial fibrillation treatment. This strategic move concentrates resources on a single electrophysiology platform, suggested to offer a unique combination of speed, safety, and durable pulmonary vein isolation. The company's investment narrative now hinges on the success of its nPulse AFib catheter program, supported by strong early clinical results, while balancing risks associated with a high valuation and ongoing losses.
Pulse Biosciences shifts focus to cardiac catheter program
Pulse Biosciences (NASDAQ:PLSE) is reallocating resources to prioritize its nPulse Cardiac Catheter Ablation System for atrial fibrillation, citing strong clinical data from a European feasibility study. The study demonstrated high procedural success and sustained efficacy, leading to significant stock performance. Although the company remains unprofitable, analysts anticipate sales growth and future research efforts will focus on the nPulse program's pivotal IDE study in the US and Europe.
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
Pulse Biosciences has strategically realigned its resources to accelerate the development and commercialization of its nPulse Cardiac Catheter Ablation System, following exceptional long-term clinical data from a European feasibility study. The data demonstrated 96% sustained success at 12 months for treating Atrial Fibrillation (AFib) with high procedural efficiency and a low rate of serious adverse events. This prioritization includes dedicating the majority of R&D and clinical investment to the cardiac catheter program while streamlining other ongoing projects.
Responsive Playbooks and the PLSE Inflection
Pulse Biosciences Inc (NASDAQ: PLSE) is experiencing a breakout, with AI models generating three distinct trading strategies for different risk profiles. Sentiment readings across horizons are divergent, suggesting choppiness, but if sustained, higher levels are expected despite elevated downside risk as no additional long-term support signals remain. The strategies include position trading, momentum breakout, and risk hedging, with specific entry, target, and stop loss zones.
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Swings
Pulse Biosciences (PLSE) has experienced significant share price swings, including a 6.4% gain over the past day and 14.6% over the past week. While a popular narrative suggests the company is 3.2% undervalued with a fair value of $22 per share due to advancing clinical programs, a discounted cash flow (DCF) analysis by Simply Wall St indicates a much lower fair value of $2.57, suggesting the current price of $21.30 might be expensive. Investors are encouraged to examine the underlying numbers and consider both valuation perspectives.
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Swings
Pulse Biosciences (PLSE) has seen significant share price swings recently, with a 6.4% gain over the past day and a 14.6% gain over the past week. While a popular narrative suggests the company is 3.2% undervalued with a fair value of $22 per share due to advancing clinical programs, Simply Wall St's discounted cash flow (DCF) model indicates a fair value closer to $2.57, suggesting the current share price might be expensive. Investors are encouraged to research further and consider key risks and alternative valuation models.
Pulse Biosciences enrolls first patients in thyroid cancer study
Pulse Biosciences has begun enrolling patients in a feasibility study for its nPulse Vybrance Percutaneous Electrode System, designed to treat papillary thyroid microcarcinoma. The company's stock has seen significant year-to-date growth, despite being considered overvalued by InvestingPro analysis, which also highlights the company's unprofitability. This study aims to evaluate the system as a potential alternative to surgery or serial surveillance for low-risk thyroid cancer.
Pulse Biosciences Launches Thyroid Cancer Feasibility Study
Pulse Biosciences (PLSE) has initiated a first-in-human feasibility study for its Vybrance Percutaneous Electrode System to treat small papillary thyroid microcarcinoma, enrolling the first patients on March 12, 2026. This multicenter study will evaluate the safety and effectiveness of the FDA-cleared device in targeting tumors under 1.5 cm using nsPFA energy for non-thermal ablation, aiming to expand its application in minimally invasive oncology treatments. Despite the positive clinical advancements, analysts maintain a "Hold" rating on PLSE stock due to financial challenges like minimal revenue and elevated cash burn.
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
Pulse Biosciences, Inc. has announced the first patient enrollments in a multicenter feasibility study for the treatment of malignant thyroid tumors using its nPulse™ Vybrance™ Percutaneous Electrode System. The study will evaluate the safety and effectiveness of the nPulse technology for papillary thyroid cancer tumors less than 1.5 cm, with initial procedures successfully completed at Sarasota Memorial Health Care System and The University of Texas MD Anderson Cancer Center. This represents a significant step towards potentially offering a minimally invasive, nonthermal alternative to surgery for low-risk thyroid cancer patients.
Pulse Biosciences (Nasdaq: PLSE) enrolls first thyroid cancer patients
Pulse Biosciences (Nasdaq: PLSE) announced it has enrolled the first patients in a multi-center, first-in-human feasibility study for its nPulse Vybrance Percutaneous Electrode System. This study aims to evaluate the safety and effectiveness of the system in treating T1N0M0 papillary thyroid microcarcinoma, a common low-risk thyroid cancer, using Nanosecond Pulsed Field Ablation (nsPFA). Initial procedures have been successfully completed at Sarasota Memorial Health Care System and The University of Texas MD Anderson Cancer Center, with a total of 30 patients planned for enrollment.
Pulse Biosciences (PLSE) reports 74% benign thyroid nodule reduction in nsPFA study
Pulse Biosciences announced positive long-term clinical data from its nPulse Vybrance Percutaneous Electrode System study for benign thyroid nodules, demonstrating a 74% average volume reduction and no regrowth over 15-22 months. The study, which followed 21 patients, also reported no serious adverse events and high patient satisfaction, supporting the potential durability and tolerability of this nonthermal ablation approach. The company expects to clarify its plans for non-cardiac nsPFA markets in the second half of 2026.
Durable Thyroid Nodule Ablation Data Could Be A Game Changer For Pulse Biosciences (PLSE)
Pulse Biosciences recently released promising long-term data from its first-in-human study of the nPulse Vybrance Percutaneous Electrode System, demonstrating sustained benign thyroid nodule volume reduction without regrowth or serious adverse events. This data suggests the potential for durable, organ-sparing thyroid treatments and could significantly impact Pulse Biosciences' investment narrative and growth prospects. While the commercialization path has variables like a recent change in commercial leadership, analysts project substantial revenue and earnings growth for the company by 2028.
Pulse Biosciences (PLSE) Reports Promising Long-Term Outcomes for Thyroid Nodule Treatment
Pulse Biosciences (PLSE) has presented promising long-term clinical data for its nPulse Vybrance Percutaneous Electrode System in treating benign thyroid nodules, showing a 74% average reduction in nodule volume with no regrowth or serious adverse events over 15-22 months. Despite these positive clinical outcomes, the company faces significant financial challenges, including negative operating and net margins, and has seen insider selling. Investors are advised to consider both the innovative technology's potential and the company's financial health and insider activity.
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Pulse Biosciences announced positive long-term clinical data from its nPulse Vybrance System First-in-Human study for benign thyroid nodule ablation. The study demonstrated an average of 74% volume reduction of treated nodules 15-22 months post-treatment, with no regrowth, high patient satisfaction, and no serious adverse events. These results highlight the potential of their proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for durable, non-thermal treatment of benign thyroid nodules.
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Pulse Biosciences announced positive long-term clinical data from its nPulse Vybrance Percutaneous Electrode System's first-in-human study for benign thyroid nodule ablation. The study demonstrated an average 74% volume reduction of treated nodules at 15-22 months post-treatment, with sustained improvement, no regrowth, and no serious adverse events. Patients reported high satisfaction regarding cosmetic appearance and overall treatment, highlighting the potential durability and effectiveness of the nsPFA technology.
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Pulse Biosciences, Inc. announced its plan to present at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 18, 2026, at 10:40 am ET. The company will discuss its novel nPulse™ technology, which uses Nanosecond Pulsed Field Ablation (nsPFA™) energy for health innovation, including treatments for atrial fibrillation and surgical soft tissue ablation. A webcast of the presentation will be available on the company's investor website.
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Momentum
Pulse Biosciences (PLSE) has experienced significant share price momentum, with a 32% return in the last month and a 3-year return of approximately 7x, but a 5-year decline of 37.2%. Analysts suggest the company is 17.7% undervalued with a fair value of $22, driven by advancing clinical programs, despite high quarterly costs and a high P/B ratio compared to the industry. The article encourages investors to consider the mixed signals and evaluate both risks and opportunities.
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Pulse Biosciences, Inc. announced its plan to present at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Wednesday, March 18, 2026, at 10:40 am ET. The company will discuss its novel nPulse™ technology, which uses Nanosecond Pulsed Field Ablation™ (nsPFA™) energy to non-thermally clear cells. A webcast of the presentation will be available on the company's investor website.
Pulse Biosciences' nPulse Vybrance System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
Pulse Biosciences announced that its nPulse Vybrance System for soft tissue ablation, specifically benign thyroid ablation, will be prominently featured at the North American Society for Interventional Thyroidology 2026 meeting. The company will present long-term follow-up data from its nPulse Vybrance feasibility study and participate in a product theatre presentation discussing the potential of nonthermal ablation with nsPFA energy. This highlights the company's commitment to advancing the treatment of benign thyroid nodules and other conditions using its proprietary nanosecond PFA technology.
Pulse Biosciences at TD Cowen Conference: NSPFA Technology Shines
Pulse Biosciences presented its nanosecond pulsed field ablation (NSPFA) technology at the TD Cowen 46th Annual Health Care Conference, showcasing positive outcomes from a European study on atrial fibrillation (AFib). The company emphasized its extensive patent estate, significant cash reserves for clinical trials through 2027, and plans to expand its EP, cardiac surgery, and soft tissue ablation programs, including an initial oncology study. Pulse Biosciences believes its novel NSPFA technology offers unparalleled efficacy and speed in AFib treatment compared to existing methods.
Thyroid experts review 15–22 month data on Pulse nPulse ablation
Pulse Biosciences announced that its nPulse™ Vybrance™ System will be featured at the North American Society for Interventional Thyroidology meeting from March 6-7, 2026. The presentations will highlight long-term follow-up data (15-22 months) from a feasibility study on benign thyroid nodule ablation using nanosecond Pulsed Field Ablation (nsPFA) technology. Experts will discuss the durability of volume and symptom reduction and the potential of non-thermal ablation with this technology.
